Dublin, Nov. 27, 2024 (GLOBE NEWSWIRE) — The “U.S. Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), Indication, Study Design, Indication by Study Design, Sponsor, Service, and Segment Forecasts, 2025-2030” report has been added to ResearchAndMarkets.com’s offering.
The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.
The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry’s growth.
U.S. Clinical Trials Market Report Highlights
- In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
- By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
- Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
The leading players in the U.S. Clinical Trials market include:
- IQVIA
- Fortrea Inc.
- PAREXEL International Corporation
- Thermo Fisher Scientific Inc.
- Charles River Laboratories
- ICON Plc
- Wuxi AppTec
- Medpace
- Syneos Health
- AstraZeneca
- Merck & Co.
- Eli Lilly
- Novo Nordisk
- Pfizer
- Caidya
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $40.56 Billion |
| Forecasted Market Value (USD) by 2030 | $57.79 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | United States |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. Regulatory Landscape
3.4. Technological Landscape
3.5. Pricing Model Analysis
3.6. Clinical Trial Volume Analysis, 2024
3.7. U.S. Clinical Trials Market Analysis Tools
3.8. Product Pipeline Analysis by Stage
3.8.1. Therapeutics in Development
3.8.2. Vaccines in Development
Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
4.3. Phase I
4.4. Phase II
4.5. Phase III
4.6. Phase IV
Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
5.3. Interventional
5.4. Observational
5.5. Expanded Access
Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
6.3. Autoimmune/Inflammation
6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2. Rheumatoid Arthritis
6.3.3. Multiple Sclerosis
6.3.4. Osteoarthritis
6.3.5. Irritable Bowel Syndrome (IBS)
6.4. Pain Management
6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4.2. Chronic Pain
6.4.3. Acute Pain
6.5. Oncology
6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2. Blood Cancer
6.5.3. Solid Tumors
6.6. CNS Conditions
6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2. Epilepsy
6.6.3. Parkinson’s Disease (PD)
6.6.4. Huntington’s Disease
6.6.5. Stroke
6.6.6. Traumatic Brain Injury (TBI)
6.6.7. Amyotrophic Lateral Sclerosis (ALS)
6.6.8. Muscle Regeneration
6.7. Diabetes
6.8. Obesity
6.9. Cardiovascular
Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
7.3. Autoimmune/Inflammation
7.4. Pain Management
7.5. Oncology
7.6. CNS Conditions
7.7. Diabetes
7.8. Obesity
7.9. Cardiovascular
Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
8.3. Protocol Designing
8.4. Site Identification
8.5. Patient Recruitment
8.6. Laboratory Services
8.7. Bioanalytical Testing Services
8.8. Clinical Trial Data Management Services
Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
9.3. Pharmaceutical & Biopharmaceutical Companies
9.4. Medical Device Companies
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.1.1. Market Leaders
10.1.2. Emerging Players
10.2. Market Position Analysis, 2024
10.3. Key Company Profiles
- IQVIA
- Fortrea
- PAREXEL
- Thermo Fisher Scientific
- Charles River Laboratories
- ICON Plc
- Wuxi AppTec
- Medpace
- Syneos Health
- AstraZeneca
- Merck
- Eli Lilly
- Novo Nordisk
- Pfizer
- Caidya
For more information about this report visit https://www.researchandmarkets.com/r/beuqnn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- U.S. Clinical Trials Market
